SDK1 and non-small cell lung carcinoma: The patient was treated with SAF-189s (160 mg per day) as a first-line therapy and went into continuous remission, with a 12 months progression-free survival at the last follow-up.<h4>Conclusion</h4>This is the first case of <i>SDK1-ALK</i> fusion with an excellent response to an ALK inhibitor, which will provide better understanding of ALK-TKI applications for NSCLC patients with <i>ALK</i> fusion in the future.